NVDA · News · 20260923N

AI Drug-Modeling Collaboration

NVIDIA CORP · 2026-09-23 · Importance 34 · Surprise 42

Iambic Therapeutics, an NVIDIA- and Qatar Investment Authority-backed AI drug-discovery company, filed for a U.S. IPO and announced a multiyear research collaboration with AbbVie. AbbVie will pay $40 million upfront and may pay up to $670 million in milestone payments. The collaboration covers AI-assisted drug design in immunology, neuroscience, and oncology, strengthening NVIDIA’s life-sciences software and partner ecosystem.

Key facts

• NVIDIA backed Iambic Therapeutics, which filed for a U.S. IPO and simultaneously announced a multi-year research collaboration with AbbVie that involves an upfront payment of $40 million and potential milestone payments of up to $670 million. source